Form 4: ImmunityBio CFO David Sachs Reports Stock Transactions Following RSU Vesting
SEC Form 4 Filing
David Sachs, CFO of ImmunityBio, reports the vesting of restricted stock units (RSUs) and subsequent disposition of shares to cover tax obligations.
Summary
- On February 22, 2025, David Sachs, the CFO of ImmunityBio, had 40,650 restricted stock units (RSUs) vest.
- Following the vesting, 15,860 shares were disposed of at a price of $3.42 to cover tax obligations.
- After these transactions, Sachs directly owns 225,620 shares of ImmunityBio common stock.
- Sachs also directly owns 81,301 derivative securities in the form of restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock transactions, with no inherent positive or negative implications for the company's performance.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the transactions of company insiders.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect routine executive compensation adjustments.
Key Dates
| Date | Description |
|---|---|
| 02/22/2024 | Vesting commencement date for the RSU award |
| 02/21/2025 | Closing price of ImmunityBio's common stock used to calculate shares withheld |
| 02/22/2025 | Date of RSU vesting and stock disposition |
| 02/25/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.